Press Release Biocartis Group NV: Biocartis Announces Planned Operational Reorganization and Cost Reduction Program
Press Release Biocartis Group NV: Biocartis Announces Planned Operational Reorganization and Cost Reduction Program
PRESS RELEASE
新聞稿
REGULATED INFORMATION – INSIDE INFORMATION
受監管的資訊-內幕消息
15 June 2023, 17:15 CEST
2023年6月15日，中部夏令時間17：15
BIOCARTIS ANNOUNCES PLANNED OPERATIONAL REORGANIZATION AND COST REDUCTION PROGRAM
Biocartis宣佈計劃中的運營重組和成本降低計劃
- Focusing investments on near-term product revenue generation and strategic partnerships that are expected to drive sustainable growth
- Approximately EUR 18 million of annualized cost reductions
- Cost reductions across the organization to create a clear path to break-even EBITDA1 by the end of 2024
- Have engaged in constructive dialogue with key creditors and planning to engage an international investment bank to assist in developing a recapitalization plan for the Company
- 將投資重點放在近期產品創收和策略性有望推動可持續增長的合作夥伴關係
- 年化成本降低約1800萬歐元
- 降低整個組織的成本，以為實現EBITDA盈虧平衡創造一條清晰的道路1到2024年底
- 進行了建設性的對話帶鑰匙債權人 和計劃接洽一位國際人士投資銀行 協助開發一個資本重組為公司制定計劃
Mechelen, Belgium, 15 June 2023 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces a planned reorganization and cost reduction program. The plan projects to reduce operating expenses by an annualized EUR 18 million, and is expected to lead to break-even EBITDA by the end of 2024. The Company plans to focus its investments on profitable revenue generation and strategic partnerships that are expected to drive sustainable growth and shareholder value. The plan aims at creating a self-sustaining business as a basis for a recapitalization that would secure the Company's remaining funding needs and enable value appreciation for all stakeholders.
梅切倫比利時，2023年6月15日--創新型分子診斷公司Biocartis Group NV(“公司”或“Biocartis”)(泛歐交易所布魯塞爾股票代碼：BCART)今天宣佈了一項計劃中的重組和降低成本計劃。該計劃預計每年減少1800萬歐元的運營費用，預計到2024年底實現盈虧平衡。該公司計劃將其投資重點放在盈利的創收和戰略合作夥伴關係上，以期推動可持續增長和股東價值。該計劃旨在創建一個自給自足的業務，作為資本重組的基礎，以確保公司剩餘的資金需求，並使所有利益相關者能夠實現價值增值。
This planned reorganization enables a shift towards profitability through an increased focus on partner funded test menu expansion and a more targeted US commercial strategy to increase oncology test utilization.
這一計劃中的重組通過更多地關注合作夥伴資助的測試菜單擴展以及更有針對性的美國商業戰略來提高腫瘤學測試的利用率，從而實現了向盈利的轉變。
Commenting on the planned reorganization, Roger Moody, Chief Executive Officer of Biocartis, said: "This reorganization is the first step necessary to create a clear path to financial independence by focusing on near-term growth from our existing business and delivering on our strategic partnership agreements that provide long-term value. I am confident that the streamlined organization will be able to continue to build on the strengths of our fully automated molecular platform with its unmatched ease-of-use, turn-around-time and sample versatility in oncology. We are fortunate to have and we fully support our trusted partnerships that include objectives to expand the number of tests that deliver fast and accurate results to cancer patients with currently unmet needs. Turning to our next steps, I look forward to working with our investors to secure the funds needed to achieve break-even EBITDA and recapitalize the balance sheet to clear the way for meaningful shareholder value creation."
Biocartis首席執行官羅傑·穆迪在評論計劃中的重組時表示：“這一重組是通過專注於我們現有業務的短期增長並履行我們提供長期價值的戰略合作夥伴關係協定，創造一條明確的財務獨立道路所必需的第一步。我相信，精簡後的組織將能夠繼續利用我們的全自動化分子平臺的優勢，在腫瘤學方面具有無與倫比的易用性、周轉時間和樣本通用性。我們很幸運地擁有並全力支持我們值得信賴的合作夥伴關係，其中包括擴大檢測數量的目標，這些檢測可以為目前未得到滿足需求的癌症患者提供快速準確的結果。談到我們的下一步行動，我期待著與我們的投資商以確保實現盈虧平衡EBITDA所需的資金，並對資產負債表進行資本重組，為有意義的股東價值創造掃清道路。
The reorganization includes the intention to reduce employment globally by approximately 140 positions (approximately 25% of the workforce), and includes a number of people employed in Biocartis' Belgian entities which triggers the application of the Belgian rules on collective dismissals. Consequently, a declaration of intent of the collective dismissal has been filed today in accordance with the Belgian rules on collective dismissals.
此次重組包括打算在全球範圍內裁減約140個職位(約佔勞動力的25%)，幷包括一些受僱於Biocartis比利時實體的人，這引發了比利時關於集體解僱的規則的適用。因此，根據比利時關於集體解僱的規則，今天提交了一份關於集體解僱的意向聲明。
The Company has engaged in constructive dialogue with key creditors and is planning to engage an international investment bank to assist in the development of a strategy and implementation of a recapitalization of the Company.
該公司與主要債權人進行了建設性對話，並計劃聘請一家國際投資銀行協助制定戰略和實施公司資本重組。
As part of the reorganization Piet Houwen, the Company's Chief Operating Officer, has submitted his resignation effective 1 September 2023.
作為重組的一部分，公司首席運營官皮特·侯文已提交辭呈，自2023年9月1日起生效。
As a result of the uncertainty related to the operational reorganization, the Company withdraws its 2023 outlook at least until the publication of its financial results for H1 2023 on 31 August 2023.
由於經營重組的不確定性，本公司撤回2023年展望，直至2023年8月31日公佈2023年上半年財務業績。
--- END ---
-完--
More information:
Corporate Communications & Investor Relations Biocartis
e-mail ir@biocartis.com
tel +32 15 632 600
更多資訊：
企業傳播與投資者關係Biocartis
電子郵件：ir@biocartis.com
電話：+32 15 632 600
@Biocartis_
@Biocartis_
About Biocartis
關於Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis. More information: . Follow us on Twitter: @Biocartis_.
Biocartis(泛歐交易所布魯塞爾股票代碼：BCART)是一家創新的分子診斷(MDX)公司，提供下一代診斷解決方案，旨在改善臨床實踐，造福患者、臨床醫生、付款人和行業。Biocartis專有的MDX Idylla平臺是一個完全自動化的從樣品到結果的實時聚合酵素鏈式反應(Polymerase Chain Reaction)系統，可以在幾乎任何環境下從幾乎任何生物樣本提供準確、高度可靠的分子資訊。Biocartis正在開發和營銷一種不斷擴大的測試菜單，以滿足關鍵的未得到滿足的臨床需求，重點放在腫瘤學上，這是全球MDX市場增長最快的部分。今天，Biocartis提供黑色素瘤、結直腸癌和肺癌以及新冠肺炎、流感、呼吸道合胞病毒和膿毒症的檢測。詳細資訊：。在Twitter上關注我們：@Biocartis_。
Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.
This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Biocartis和Idylla是在歐洲、美國和其他國家的註冊商標。Biocartis和Idylla商標和徽標是Biocartis擁有的商標。請參考產品標籤，瞭解每種生物卡特斯產品的適用目標用途。
本新聞稿不適用於在任何司法管轄區直接或間接分發，因為這樣做是非法的。任何閱讀本新聞稿的人都應瞭解並遵守任何此類限制。Biocartis對任何人違反任何此類限制不承擔任何責任。本新聞稿不構成在任何司法管轄區出售或購買證券的要約或邀請。如果沒有在美國證券交易委員會註冊或根據修訂後的1933年美國證券法獲得註冊豁免，Biocartis的證券不得在美利堅合眾國發行或出售。
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
前瞻性陳述
本新聞稿中的某些陳述、信念和意見是前瞻性的，它們反映了公司或適當時公司董事或管理人員對未來事件的預期和預測，如公司的經營結果、財務狀況、流動性、業績、前景、增長、戰略和公司所處的行業。就其性質而言，前瞻性陳述涉及許多風險、不確定性、假設和其他因素，可能導致實際結果或事件與前瞻性陳述明示或暗示的結果或事件大相徑庭。這些風險、不確定性、假設和因素可能對本文所述計劃和事件的結果和財務影響產生不利影響。許多因素，包括但不限於需求、競爭和技術的變化，可能會導致實際事件、表現或結果與任何預期的發展大不相同。本新聞稿中包含的有關過去趨勢或活動的前瞻性陳述並不是對未來業績的保證，也不應被視為此類趨勢或活動將在未來繼續下去的表述。此外，即使實際結果或事態發展與本新聞稿中的前瞻性陳述一致，這些結果或事態發展也可能不代表未來的結果或事態發展。對於此類前瞻性陳述的準確性或公正性，不作任何陳述或保證。因此，公司明確表示不承擔任何義務或承諾因預期的任何變化或這些前瞻性陳述所基於的事件、條件、假設或情況的任何變化而發佈對本新聞稿中任何前瞻性陳述的任何更新或修訂，除非法律或法規明確要求這樣做。公司或其顧問或代表、其任何子公司或任何此類人士的高級管理人員或員工均不保證此類前瞻性陳述所依據的假設沒有錯誤，也不對本新聞稿中包含的前瞻性陳述的未來準確性或預測發展的實際發生承擔任何責任。您不應過分依賴前瞻性陳述，這些陳述僅反映了本新聞稿發佈之日的情況。
1 Earnings before interest, taxes, depreciation and amortization
1未計利息、稅項、折舊及攤銷前收益
譯文內容由第三人軟體翻譯。